Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo

Cancer Letters

Volumn 226, Issue 1, 2005, Pages 37-47

  Hara, Fumikata ^a   Aoe, Motoi ^a   Doihara, Hiroyoshi ^a   Taira, Naruto ^a   Shien, Tadahiko ^a   Takahashi, Hirotoshi ^a   Yoshitomi, Seiji ^a   Tsukuda, Kazunori ^a   Toyooka, Shinichi ^a   Ohta, Tetsuya ^a   Shimizu, Nobuyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

EGFR; Esophageal squamous cell carcinoma; Gefitinib

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 21744460198     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.12.025     Document Type: Article

References (40)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Estimating the world cancer burden: Globocan 2000 Int. J. Cancer 94 2001 153 156
2. H. Kuwano, N. Sadanaga, M. Watanabe, M. Yasuda, T. Nozoe, and K. Sugimachi Oesophageal cancer composed of mixed histological types Eur. J. Surg. Oncol. 22 1996 225 231
3. T. Lerut, W. Coosemans, P.D. Leyn, D.V. Raemdonck, G. Deneffe, and G. Decker Treatment of esophageal carcinoma Chest 116 Suppl. 6 1999 463S 465S
4. M. Koshy, N. Esiashvilli, J.C. Landry, C.R. Thomas Jr., and R.H. Matthews Multiple management modalities in esophageal cancer: combined modality management approaches Oncologist 9 2004 147 159
5. S. Cohen, G. Carpenter, and L. King Jr. Epidermal growth factor-receptor-protein kinase interactions, co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity J. Biol. Chem. 255 1980 4834 4842
6. N.E. Hynes, K. Horsch, M.A. Olayioye, and A. Badache The ErbB receptor tyrosine family as signal integrators Endocr. Relat. Cancer 8 2001 151 159
7. J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 103 2000 211 215
8. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signaling network Nat. Rev. Mol. Cell. Biol. 2 2001 127 137
9. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, and M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 2000 4885 4892
10. F. Ciardiello, R. Caputo, G. Borriello, D.D. Bufalo, A. Biroccio, and G. Zupi ZD1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug resistant MCF-7ADR human breast cancer cells Int. J. Cancer 98 2002 463 469
11. C. Bianco, G. Tortora, R. Bianco, R. Caputo, B.M. Veneziani, and R. Capto Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) Clin. Cancer Res. 8 2002 3250 3258
12. P.A. Janne, M.L. Taffaro, R. Salgia, and B.E. Johnson Inhibition of epidermal growth factor receptor signaling in malignant pleural methothelioma Cancer Res. 62 2002 5242 5247
13. K. Iihara, H. Shiozaki, H. Tahara, K. Kobayashi, M. Inoue, and S. Tamura Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation Cancer 71 1993 2902 2909
14. S. Ozawa, M. Ueda, N. Ando, O. Abe, and N. Shimizu High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas Int. J. Cancer 39 1987 333 337
15. S. Ozawa, M. Ueda, N. Ando, N. Shimizu, and O. Abe Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas Cancer 63 1989 2169 2173
16. Y. Shimada, M. Imamura, G. Watanabe, S. Uchida, H. Harada, and T. Makino Prognostic factor of oesophageal squamous cell carcinoma from the perspective of molecular biology Br. J. Cancer 80 1999 1281 1288
17. Y. Kitagawa, M. Ueda, N. Ando, S. Ozawa, N. Shimizu, and M. Kitajima Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma Clin. Cancer Res. 2 1996 909 914
18. S. Ozawa, M. Ueda, N. Ando, N. Shimizu, and O. Abe Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas Cancer 63 1989 2169 2173
19. Y. Itakura, H. Sasano, C. Shiga, Y. Furukawa, K. Shiga, and S. Mori Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification Cancer 74 1994 795 804
20. K. Hickey, D. Grehan, I.M. Reid, S. O'Braiain, T.N. Walsh, and T.P. Hennessy Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemotherapy Cancer 74 1994 1693 1698
21. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, W.D. McGuinn Jr., and D. Morse United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10 2004 1212 1218
22. K. Nakagawa, T. Tamura, S. Negoro, S. Kudoh, N. Yamamoto, and N. Yamamoto Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann. Oncol. 14 2003 922 930
23. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J. Clin. Oncol. 21 2003 2237 2246
24. J.D. Jacquemier, F.M. Penault-Llorca, F. Bertucci, Z.Z. Sun, G.F. Houvenaeghel, and J.A. Geneix Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis J. Pathol. 184 1998 130 135
25. M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S. Ueda, and H. Kinoshita Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther. 3 2004 465 472
26. S. Shintani, C. Li, M. Mihara, J. Yano, N. Terakado, and K. Nakashiro Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines Oral Oncol. 40 2004 43 51
27. E.D. Gennaro, M. Barbarino, F. Bruzzese, S.D. Lorenzo, M. Caraglia, and A. Abbruzzese Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells J. Cell. Physiol. 195 2003 139 150
28. B. Li, C.M. Chang, M. Yuan, W.G. McKenna, and H.K. Shu Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas Cancer Res. 63 2003 7443 7450
29. M.L. Janmaat, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin. Cancer Res. 9 2003 2316 2326
30. Q.B. She, D. Solit, A. Basso, and M.M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin. Cancer Res. 9 2003 4340 4346
31. C.J. Bruns, C.C. Solorzano, M.T. Harbison, S. Ozawa, R. Tsan, and D. Fan Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res. 60 2000 2926 2935
32. A. Hirata, S. Ogawa, T. Kometani, T. Kuwano, S. Naito, and M. Kuwano ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res. 62 2002 2554 2560
33. N. Magne, J.L. Fischel, A. Dubreuil, P. Formento, M.F. Poupon, and P.L. Puig Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br. J. Cancer 86 2002 1518 1523
34. T. Suzuki, T. Nakagawa, H. Endo, T. Mitsudomi, A. Masuda, and Y. Yatabe The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status Lung Cancer 42 2003 35 41
35. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, and S.D. Placido Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053 2063
36. R. Perez-Soler The role of erlotinib (Tarceva OSI 774) in the treatment of non-small cell lung cancer Clin. Cancer Res. 15 2004 4238s 4240s
37. M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, and L. Vigano Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level J. Cell. Physiol. 198 2004 259 268
38. J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, and J. Arribas ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin. Cancer Res. 9 2003 1274 1283
39. Y. Wang, J. Chen, L. Meng, J. Liu, D. Du, and Y. Zou A histopathologic and immunohistochemical study of prognostic factors in esophageal squamous cell carcinoma Zhonghua Bing Li Xue Za Zhi 29 2000 267 271
40. M. Akamatsu, T. Matsumoto, K. Oka, S. Yamasaki, H. Sonoue, and Y. Kajiyama c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma Int. J. Radiat. Oncol. Biol. Phys. 57 2003 1323 1327